{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:32:24Z","timestamp":1772613144011,"version":"3.50.1"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T00:00:00Z","timestamp":1366934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Several classes of antidiabetic agents have been introduced into the market place over the past dozen years. As our understanding of the underlying pathophysiology of type 2 diabetes has advanced, attempts have been made to address these defects specifically. This brief review focuses on our experience with two such pharmacological approaches: (i) a synthetic amylin analog addressing amylin deficiency; and (ii) a dopaminergic agonist, focused on enhancing the lowered dopaminergic tone in patients with type 2 diabetes. Importantly, the use of these agents is not associated with hypoglycemia or weight gain.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1753-0407.12034","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T06:00:12Z","timestamp":1362463212000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine\u2010<scp>QR<\/scp> (2\u578b\u7cd6\u5c3f\u75c5\u6cbb\u7597\u65b0\u836f\uff1a\u7b2c1\u90e8\u5206.\u666e\u5170\u6797\u80bd\u4e0e\u6eb4\u9690\u4ead\u2010QR)"],"prefix":"10.1111","volume":"5","author":[{"given":"George","family":"Grunberger","sequence":"first","affiliation":[{"name":"Grunberger Diabetes Institute  Bloomfield Hills Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)91325-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1999.276.1.E19"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073858407311100"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S3225"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2000.278.6.G946"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397357"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050646"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-34790"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.32022"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1732-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00217.2007"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/VHRM.S1978","article-title":"Pramlintide, the synthetic analogue of amylin: Physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk","volume":"4","author":"Hoogwerf BJ","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.20.3.137"},{"issue":"1","key":"e_1_2_6_15_1","first-page":"A113","article-title":"Effects of six months of administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes","volume":"48","author":"Fineman M","year":"1999","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_6_16_1","first-page":"A109","article-title":"Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type1 diabetes during treatment for 52 weeks","volume":"49","author":"Gottlieb A","year":"2000","journal-title":"Diabetes"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.4.724"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01319.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.6.987"},{"key":"e_1_2_6_20_1","first-page":"A232","article-title":"Pramlintide therapy in addition to insulin in type 2 diabetes: Effect on metabolic control after 6 months","volume":"42","author":"Gottlieb A","year":"2007","journal-title":"Diabetologia"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-837662"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.76"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.8.1179"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400683"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2580"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP09044.ORR1"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0589"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0395"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0641"},{"issue":"1","key":"e_1_2_6_32_1","first-page":"A285","article-title":"Pramlintide\u2010induced shift towards euglycemia based on SMBG profiles in T2DM","volume":"61","author":"Herrmann K","year":"2012","journal-title":"Diabetes"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000054508"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903501544"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.6.667"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1697"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(95)90041-1"},{"key":"e_1_2_6_38_1","first-page":"464","article-title":"Circadian rhythms regulate the expression of the thrifty genotype\/phenotype","volume":"4","author":"Meier AH","year":"1996","journal-title":"Diabetes Rev"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1154"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0064"},{"issue":"1","key":"e_1_2_6_41_1","first-page":"A99","article-title":"Bromocriptine (Ergoset) improves glycemic control in type 2 diabetics on insulin","volume":"48","author":"Schwartz S","year":"1999","journal-title":"Diabetes"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.10.1683"},{"key":"e_1_2_6_43_1","first-page":"S372","article-title":"Quick release bromocriptine (CyclosetTM) improves glycaemic control in patients with diabetes failing metformin\/sulfonylurea combination therapy","volume":"51","author":"Scranton RE","year":"2008","journal-title":"Diabetologia"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2009"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.002279"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155\u20106156.1000142"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP12187.OR"}],"container-title":["Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1753-0407.12034","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.12034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:20:26Z","timestamp":1697390426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1753-0407.12034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,26]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/1753-0407.12034"],"URL":"https:\/\/doi.org\/10.1111\/1753-0407.12034","archive":["Portico"],"relation":{},"ISSN":["1753-0393","1753-0407"],"issn-type":[{"value":"1753-0393","type":"print"},{"value":"1753-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,26]]},"assertion":[{"value":"2013-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}